野村 弘行

Medicine & Life Sciences

1. Adjuvant Chemotherapy 8%
2. Bevacizumab 7%
3. Biomarkers 9%
4. Breast Neoplasms 9%
5. Carboplatin 28%
6. Carcinogenesis 11%
7. Carcinoma 18%
8. Carcinosarcoma 10%
9. Choriocarcinoma 9%
10. Cisplatin 12%
11. DNA 9%
12. DNA Mismatch Repair 17%
13. Docetaxel 10%
14. Drug Therapy 19%
15. Endometrial Hyperplasia 12%
16. Endometrial Neoplasms 100%
17. Endometrioid Carcinoma 8%
18. Epigenomics 9%
19. Fallopian Tubes 19%
20. Genes 16%
21. Hereditary Breast and Ovarian Cancer Syndrome 7%
22. Hereditary Nonpolyposis Colorectal Neoplasms 18%
23. Hysteroscopy 9%
24. Irinotecan 20%
25. Japan 16%
26. liposomal doxorubicin 10%
27. Lymph Node Excision 8%
28. Lymph Nodes 15%
29. MicroRNAs 12%
30. Microsatellite Instability 8%
31. Mutation 12%
32. Narrow Band Imaging 10%
33. Neoplasm Metastasis 15%
34. Neoplasms 36%
35. Ovarian Epithelial Carcinoma 36%
36. Ovarian Neoplasms 57%
37. Ovary 10%
38. Paclitaxel 24%
39. Peutz-Jeghers Syndrome 10%
40. Platinum 14%
41. Progression-Free Survival 17%
42. Safety 7%
43. Sarcoma 10%
44. Sentinel Lymph Node 8%
45. Survival 9%
46. taxane 12%
47. Therapeutics 11%
48. Transcriptome 7%
49. Uterine Cervical Neoplasms 11%
50. Uterine Neoplasms 19%